Effectiveness of propagermanium treatment in multiple myeloma patients

European Journal of Haematology

Volumn 73, Issue 6, 2004, Pages 397-401

  Tsutsumi, Yutaka ^a   Tanaka, Junji ^b   Kanamori, Hiroe ^a   Musashi, Mio ^a   Minami, Hiina ^a   Fukushima, Arata ^a   Yamato, Hiroaki ^a   Ehira, Nobuyuki ^a   Kawamura, Takahito ^a   Obara, Shinji ^a   Ogura, Nobutaka ^a   Asaka, Masahiro ^b   Imamura, Masahiro ^b   Masauzi, Nobuo ^a  

^a Hakodate Municipal Hospital   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Interferon; Multiple myeloma; Propagermanium

Indexed keywords

CARBOXYETHYLGERMANIUM SESQUIOXIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMIPRAMINE; INTERFERON; MELPHALAN; PARAPROTEIN; PREDNISOLONE; RANIMUSTINE; VINCRISTINE; VINDESINE;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON INDUCERS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; ORGANOMETALLIC COMPOUNDS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 9444252285     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00330.x     Document Type: Article

References (30)

1. UK Myeloma Forum. British Committee for Standards in Haematology. Diagnosis and management of multiple myeloma. Br J Haematol 2001;115:522-540.
2. HIRAYAMA C, SUZUKI H, ITO M, OKUMURA M, ODA T. Propagermanium: a nonspecific immune modulator for chronic hepatitis B. J Gastroenterol 2003;38:525-532.
3. BRUTKJEWICZ RR, SUZUKI F. Biological activities and antitumor mechanism of an immunopotentiating organogermanium compound, Ge-132. In Vivo 1987;1:189-203.
4. MUNAKATA T, ARAI S, KUWANO K, FURUKAWA M, TOMITA Y. Induction of interferon production by natural killer cells by organogermanium compound, Ge-132. J Interferon Res 1987;7:69-76.
5. Aso H, SUZUKI F, YAMAGUCHI T, HAYASHI Y, EBINA T, ISHIDA N. Induction of interferon and activation of NK cells and macrophages in mice by oral administration of Ge-132, an organic germanium compound. Microbiol Immunol 1985;29:65-74.
6. ITO M, SASAKI K, TATEISHI T, YAMAUCHI M. Phase I clinical study of an immunotherapeutic agent, proxigermanium (SK-818), 2: multiple and consecutive administration study [in Japanese]. Yakuri to Chiryo 1990;18:2631-2674.
7. TAKAHASHI I, FUKUMOTO M, INAGAKI N, et al. Effect of interferon and its inducers on neutrophil chemiluminescence [in Japanese], Gan To Kagaku Ryoho 1984;11:1439-1443.
8. TANAKA N, OHIDA J, ONO M, YOSHIWARA H, BEIKA T, TERASAWA A, YAMADA J, MORIOKA S, MANNAMI T, ORITA K. Augmentation of NK activity in peripheral blood lymphocytes of cancer patients by intermittent GE-132 administration [in Japanese]. Gan To Kagaku Ryoho 1984;11:1303-1306.
9. SUZUKI F, BRUTKIEWICZ RR, POLLARD RB. Cooperation of lymphokine(s) and macrophages in expression of antitumor activity of carboxyethlgermanium sesquioxide (Ge-132). Anticancer Res 1986;6:177-182.
10. ISHIWATA Y, SUZUKI E, OTUKA T, YOKOCHI S, TASAKA F, USUDA H, MITANI T. Stimulation of cellular immune function by propagermanium [in Japanese], Oyo Yakuri 1994;47:155-164.
11. ISHIWATA Y, YOKOCHI S, OTSUKA T, MICHISHITA H, MITANI T, KURONO M. Immunological studies of proxigermanium (SK-818) - effects of proxigermanium on the delayed type hypersensitivity and antibody production [in Japanese]. Kiso to Rinshou 1990;24:301-308.
12. SUZUKI F. Antitumor mechanisms of carboxyethyl-germanium sesquoxide (Ge-132) in mice bearing Ehrlich ascites tumors [in Japanese]. Gan To Kagaku Ryoho 1987;14:127-134.
13. KOBAYASHI H, KOMURO T, FURUE H. Effect of combination immunochemotherapy with an organogermanium compound, Ge-132, and antitumor agents on C57BL/6 mice bearing Lewis lung carcinoma (3LL) [in Japanese]. Gan To Kagaku Ryoho 1986;13:2588-2593.
14. SUZUKI F. Suppression of tumor growth by peritoneal macrophages isolated from mice treated with carboxyethylgermanium sesquioxide (Ge-132) [in Japanese]. Gan To Kagaku Ryoho 1985;12:2122-2128.
15. SUZUKI F, BRUTKIEWICZ RR, POLLARD RB. Ability of sera from mice treated with Ge-132, an organic germanium compound, to inhibit experimental murine ascites tumors. Br J Cancer 1985;52:757-763.
16. KUMANO N, ISHIKAWA T, KOINUMARU S, KIKUMOTO T, SUZUKI S, NAKAI Y, KONNO K. Antitumor effect of the organogermanium compound Ge-132 on the Lewis lung carcinoma (3LL) in C57BL/6(B6) mice. Tohoku J Exp Med 1985;146:97-104.
17. SATO I, YUAN BD, NISHIMURA T, TANAKA N. Inhibition of tumor growth and metastasis in association with modification of immune response by novel organic germanium compounds. J Biol Response Mod 1985;4:159-168.
18. HORI K, INOUE T, MIYADI J, INABA K, KURONO M. Studies on the metabolic fate of proxigermanium (IV) - absorption and excretion in dogs [in Japanese]. Kiso To Rinsho 1990;24:2483-2491.
19. MELLSTEDT H, AAHRE A, BJORKHOLM M, CANTELL K, HOLM G, JOHANSSON B, STRANDER H. Interferon therapy in myelomatosis. Lancet 1979;2:697.
20. QUESADA JR, HAWKINS M, HORNING S, ALEXANIAN R, BORDEN E, MERIGAN T, ADAMS F. Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. Am J Med 1984;77:427-432.
21. COSTANZI JJ, COOPER MR, SCARFFE JH, OZER H, GRUBBS SS, FERRARESI RW, POLLARD RB, SPIEGEL RJ. Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. J Clin Oncol 1985;3:654-659.
22. TAKEYAMA H, YANO K, KATAOKA T, YAMAMOTO M, EMI N, KODERA Y, KAWASHIMA K, OHNO R, YOKOMAKU S, KOBAYASHI M. Clinical study on the effect of human lymphoblastoid interferon in multiple myeloma [in Japanese]. Gan To Kagaku Ryoho 1983;10:2043-2048.
23. BRENNING G, AHRE A, NILSSON K. Correlation between in vitro and in vivo sensitivity to human leukocyte interferon in patients with multiple myeloma. Scand J Haematol 1985;35:543-549.
24. AHRE A, BJORKHOLM M, MELLSTEDT H, et al. Human leukocyte interferon and intermittent high-dose melphalan-prednisolone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden. Cancer Treat Rep 1984;68:1331-1338.
25. OHNO R, KIMURA K, AMAKI I, et al. Treatment of multiple myeloma with recombinant human leukocyte A interferon. Cancer Treat Rep 1985;69:1433-1435.
26. WISLOFF F, GULBRANDSEN N. Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients. Nordic Myeloma Study Group. Acta Oncol 2000;39:809-813.
27. Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001;113:1020-1034.
28. BJORKSTRAND B, SVENSSON H, GOLDSCHNIDT H, et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2001;27:511-515.
29. LUDWIG H, FRITZ E. Interferon in multiple myeloma - summary of treatment results and clinical implication. Acta Oncol 2000;39:815-821.
30. FRITZ E, LUDWIG H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomized trials among 3948 patients. Ann Oncol 2000;11:1427-1436.